1. Introduction {#s0005}
===============

Mitochondrial DNA depletion syndrome (MDS) is a clinically heterogeneous group of diseases associated with a reduced copy number of mitochondrial DNA in affected tissues and organs. MDS is usually classified as myopathic, encephalomyopathic, hepatocerebral, or neurogastrointestinal [@bb0005]. Hepatocerebral MDS is characterized by early-onset hepatopathy and neurological manifestations. Four genes are known to be associated with hepatocerebral MDS: *POLG1*, *DGUOK*, *C10orf2*, and *MPV17* [@bb0005], [@bb0010]. *MPV17*-related MDS is a very rare condition, for which only approximately 40 different mutations have been reported ([www.hgmd.cf.ac.uk](http://www.hgmd.cf.ac.uk){#ir0005}). In our current study, four Korean children with hepatocerebral MDS are described, and *MPV17* mutations were identified in all these patients.

1.1. Case descriptions {#s0010}
----------------------

We describe four patients from three non-consanguineous Korean families---three male and one female patient ([Table 1](#t0005){ref-type="table"}). Two patients (Patients 2 and 3) were siblings. They were born after 36--39 wks of gestation with normal birth weights [@bb0015]. Their perinatal periods were uneventful. The presenting signs included persistent neonatal jaundice in Patients 1 to 3 at 2--4 mos of age and growth retardation with elevated hepatic enzymes in Patient 4 at 12 mos of age. Out of the four patients, two were underweight (weight \< 2 SD below mean), and one had short stature (height \< 2 SD below mean). The serum aspartate transferase, alanine transferase, gamma-glutamyl transferase and total and direct bilirubin levels were elevated in all patients ([Table 1](#t0005){ref-type="table"}). The serum lactic acid level was elevated in all patients as well and the lactate/pyruvate ratio was 28--41 ([Table 1](#t0005){ref-type="table"}).

Abdominal ultrasound showed diffusely increased hepatic parenchymal echogenicity in all patients. Histological examination revealed fatty changes and the ballooning of hepatocytes with severe cholestasis and septal fibrosis with ductal damages. Electron microscopic examination revealed hepatocytes with densely packed mitochondria with disoriented or lost cristae ([Fig. 1](#f0005){ref-type="fig"}). Hypoglycemic episodes were recurrent in Patients 1--3. Patient1 had nephrocalcinosis. Seizures did not develop in any patient, but profound motor hypotonia and developmental delay were evident in all four cases. Patient 1 had peripheral motor neuropathy, and Patient 2 had horizontal nystagmus and retinal dystrophy. Brain imaging studies performed in all patients between 3 and 26 mos of age were unremarkable, except for delayed myelination in Patient3. Genetic testing was performed on all patients for *POLG1*, *DGUOK*, and *MPV17* genes using genomic DNA from the peripheral leukocytes, and all patients had mutations in the *MPV17* gene ([Table 1](#t0005){ref-type="table"}). Four different *MPV17* mutations were found. Three mutations, p.Gly94Arg, p.Pro98Leu, and p.Leu151Profs\*39, were previously reported [@bb0025], [@bb0035]. The other mutation, p.Val66Glu, was a novel mutation and was not found in the 1000 Genomes database ([www.1000genomes.org](http://www.1000genomes.org){#ir0010}). Being located in the 2nd transmembrane domain, this mutation was predicted as pathogenic by two *in silico* analyses, MutationTaster (<http://www.mutationtaster.org>) and SIFT (<http://blocks.fhcrc.org/sift/SIFT.html>). Despite conservative management, all the patients died of liver failure between 6 and 28 mos of age.

2. Discussion {#s0015}
=============

The prevalence of *MPV17*-related hepatocerebral MDS is unknown but is expected to be very rare. In addition, as more nuclear genetic defects are identified in various kinds of MDS patients, the identification of each genetic defect is becoming more complicated in these cases. Because MDS involves multiple systems, muscular, hepatic, gastrointestinal, or neuronal, the clinical classification of MDS into 1 of the 4 subgroups can be difficult in some patients with overlapping phenotypes. In this respect, multigene testing using next-generation sequencing techniques is becoming more popular for the genetic confirmation of MDS [@bb0020]. Nevertheless, our own experience indicates that these four genes can be screened in infantile patients who exhibit cholestatic hepatopathy, lactic acidosis (increased lactate/pyruvate ratio), developmental delay and motor hypotonia, as well as showing histological evidence of MDS such as an increase in dysmorphic mitochondria. Although we did not test for *C10orf2*, we identified *MPV17* mutations in all four patients.

In the liver of a patient with hepatocerebral MDS, the mitochondrial DNA copy number is profoundly reduced and mitochondrial respiratory chain activities are decreased, except complex II that is encoded by the nuclear DNA. However, these measurements were not available for our patients. Instead, we directly screened for genomic mutations in the genes responsible for this condition. We cannot conclude that *MPV17* is the most common gene responsible for hepatocerebral MDS in Korean or other East Asian populations but we suggest that *MPV17* can be the first gene to be screened in MDS patients in these populations.

To date, *MPV17* mutations have been detected as widely distributed along the coding region of its 8 exons [@bb0030], and p.Arg50Gln is the most common mutation that is only found in a homozygous state [@bb0025]. Excluding p.Arg50Gln, most mutations have been reported as private. Among the families studied here, 1 frameshift mutation---p.Leu151Profs\*39---was homozygous in the siblings, and this has been first reported in Japanese siblings with MDS [@bb0035]. In addition, p.Pro98Leu was recurrently found in two unrelated families of our patients, which was first reported in Caucasian children [@bb0025]. It remains to be seen whether these mutations are common mutations in MDS patients from Eastern Asian countries, but there are no other reports on *MPV17* mutations in these populations.

Genotype-phenotype correlations are poorly understood because fewer than 50 patients have been identified to date, and most cases have private mutations, experience liver failure, and do not survive their first decade of life. A milder phenotype has been described only for the most common mutation---p.Arg50Gln---in some homozygotes [@bb0025]. In our present patients, the siblings with the homozygous frameshift mutation---p.Leu151Profs\*39---experienced the most rapid progression of liver failure and died within 6 mos of age.

Liver transplantation is controversial in MDS patients due to its multisystemic involvement but only conservative management is otherwise possible for this devastating condition. Due to the autosomal recessive inheritance of MDS, genetic diagnosis is very important to provide genetic counseling to affected patients and their families regarding future reproduction.
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![Histological findings in the hepatic tissues of a patient with *MPV17*-related hepatocerebral MDS (Patient1). A) Hepatocytes with macrovesicular steatosis (hematoxylin and eosin stain, × 400). B) Portal inflammation with bile ductular reaction and septal fibrosis (Masson\'s trichrome stain, × 400). C) Hepatocytes with densely packed mitochondria showing a granular appearance and loss of cristae (electron micrographs, × 120,000).](gr1){#f0005}
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Clinical and molecular findings of the 4 patients with *MPV17*-related hepatocerebral MDS.

Table 1

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                                    Patient1                                                                      Patient2                                       Patient3                                       Patient4
  ------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ---------------------------------------------------------------
  Gestational period                                                                                36 wks                                                                        37 wks                                         39 wks                                         38 wks

  Birth weight                                                                                      2955 g\                                                                       3000 g\                                        3400 g\                                        3220 g\
                                                                                                    (− 0.9 SD)                                                                    (− 0.8 SD)                                     (− 0.1 SD)                                     (− 0.4 SD)

  Age at presentation                                                                               4 mos                                                                         2 mos                                          2 mos                                          12 mos

  Hepaticmanifestations                                                                             Cholestasis                                                                   Cholestasis                                    Cholestasis                                    Cholestasis

  Steatohepatitis                                                                                   Hepatomegaly                                                                  Hepatomegaly                                   Hepatomegaly                                   

  Liver failure                                                                                     Steatohepatitis                                                               Steatohepatitis                                Steatohepatitis                                

  Liver failure                                                                                     Liver failure                                                                 Liver failure                                                                                 

  Neurologicalmanifestations                                                                        Developmental delays                                                          Developmental delays                           Developmental delays                           Developmental delays

  Hypotonia                                                                                         Hypotonia                                                                     Hypotonia                                      Hypotonia                                      

  Peripheral motor neuropathy                                                                       Horizontal nystagmus                                                                                                                                                        

  Growth parameters                                                                                 11 mos                                                                        2 mos                                          4 mos                                          24 mos

  Height                                                                                            1.2 SD                                                                        0.4 SD                                         − 1.8 SD                                       − 3.0 SD

  Weight                                                                                            − 1.0 SD                                                                      − 2.2 SD                                       − 1.9 SD                                       − 3.8 SD

  Metabolic                                                                                         Hypoglycemia                                                                  Hypoglycemia                                   Hypoglycemia                                   Lactic acidosis

  Lactic acidosis                                                                                   Lactic acidosis                                                               Lactic acidosis                                                                               

  Others                                                                                            Recurrent vomiting                                                            Recurrent vomiting                             Recurrent vomiting                             Recurrent vomiting

  Nephrocalcinosis                                                                                  Retinal dystrophy                                                                                                                                                           

  Aspartate transferase (normal range, \< 40 IU/L)/alanine transferase (normal range, \< 40 IU/L)   370/164                                                                       113/55                                         133/57                                         202/93

  Plasma lactate (normal range, 0.2--1.2 mg/dL)                                                     41.4                                                                          69.3                                           53.1                                           45.0

  Lactate/pyruvate ratio                                                                            27.6                                                                          38.5                                           40.8                                           37.8

  *MPV17* mutations                                                                                 c.\[**197T** **\>** **A**\];\[293C \> T\] (p.\[**Val66Glu**\];\[Pro98Leu\])   c.\[451dupC\];\[451dupC\]\                     c.\[451dupC\];\[451dupC\]\                     c.\[280G \> C\]; c.\[293C \> T\](p.\[Gly94Arg\];\[Pro98Leu\])
                                                                                                                                                                                  (p.\[Leu151Profs\*39\]; \[Leu151Profs\*39\])   (p.\[Leu151Profs\*39\]; \[Leu151Profs\*39\])   

  Brain MR                                                                                          Normal                                                                        Normal                                         Myelination delays                             Not done

  Outcome (cause of death)                                                                          Death at 2 yrs and 2 mos (liver failure)                                      Death at 6 mos (liver failure)                 Death at 6 mos (liver failure)                 Death at 2 yrs and 4 mos (liver failure)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SD, standard deviation; Bold character, a novel mutation.
